RedHill Biopharma

RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the study and licensing of therapeutic candidates. Its products include Talicia, Movantik, and Aemcolo. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TEL AVIV, Israel and RALEIGH, N.C., May 21, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021

TEL AVIV, Israel and RALEIGH, N.C., May 20, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021

Humanigen

They're approaching the treatment-race finish line.

Could These 2 Exciting COVID Stocks be 10-Baggers?

TEL AVIV, Israel and RALEIGH, N.C., April 9, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue

The pandemic has cut into RedHill's growing potential.

RedHill: More To Come

RedHill Biopharma Ltd. (NASDAQ:RDHL) has announced a resolution to patent litigation in the US in response to a generic version of Movantik (naloxegol) which the company acquired the global rights to, excluding Europe and Canada, from AstraZeneca in April 2020.

RedHill Biopharma announces resolution to patent litigation in the US in response to a generic version of Movantik

TEL AVIV, Israel and RALEIGH, N.C., March 25, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN Pharmaceuticals

RedHill Biopharma Ltd. (NASDAQ:RDHL) announced that it has acted on a request to provide its opaganib treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from coronavirus (COVID-19) pneumonia.

RedHill Biopharma provides opaganib treatment under compassionate use exemption for several Swiss patients suffering from coronavirus pneumonia

TEL AVIV, Israel and RALEIGH, N.C., March 22, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland

RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q4 2020 Results - Earnings Call Transcript

RedHill Biopharma Ltd (NASDAQ: RDHL) has reported FY2020 net revenue of approximately $64 million and gross profit of $27.5 million thanks to the commercialization of its Movantik and Talicia gastrointestinal drugs. The company delivered 4Q revenue of around $21.5 million, an increase of $0.5 million compared to 3Q 2020, with a 12% increase in product delivery.

RedHill Biopharma delivers revenue growth, commercial expansion and pipeline progress in FY2020 results as focused efforts pay off

Shares of Redhill Biopharma (NASDAQ:RDHL) rose 0.9% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 333.33% year over year to ($0.07), which beat the estimate of ($0.24).

Recap: Redhill Biopharma Q4 Earnings

TEL AVIV, Israel and RALEIGH, N.C., March 18, 2021 /PRNewswire/ -- Financials: Full year 2020 net revenues of approximately $64 million, with gross profit of approximately $27.5 million Solid cash balance of approximately $100 million as of March 4, 2021 Planned commercial operational breakeven by the end of 2021 Commercial Highlights : Talicia: Consistent month-over-month prescription growth despite pandemic conditions, with 52% new prescription growth in Q4/2020 compared to Q3/2020 Movantik: Market leadership position holding strong and well-positioned for further growth in 2021 R&D Highlights: Two advanced programs at the forefront of global COVID-19 novel therapeutics development: Opaganib: Ongoing global Phase 2/3 study in hospitalized patients approximately two thirds enrolled, data expected Q2/2021; Positive U.S. Phase 2 data reported RHB-107 : Ongoing U.S. Phase 2/3 study in symptomatic non-hospitalized patients RHB-204 : Ongoing Phase 3 study for pulmonary NTM disease as oral first-line treatment Management to host webcast today, at 8:30 a.m.

RedHill Biopharma Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

TEL AVIV, Israel and RALEIGH, NC, March 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its fourth quarter and full year 2020 financial results and operational highlights on Thursday, March 18, 2021.

RedHill Biopharma to Host Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Webcast on March 18, 2021

TEL AVIV, Israel and RALEIGH, NC, March 5, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present at the following upcoming virtual conferences in March: Sachs Spring Life...

RedHill to Present at Upcoming Conferences in March

TEL AVIV, Israel and RALEIGH, N.C., March 4, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 4,375,000 American...

RedHill Biopharma Announces Closing of $35 Million Bought Deal Offering of American Depositary Shares

TEL AVIV, Israel and RALEIGH, NC, March 2, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced public...

RedHill Biopharma Increases Previously Announced Bought Deal to $35 Million of American Depositary Shares

TEL AVIV, Israel and RALEIGH, N.C., March 1, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the...

RedHill Biopharma Announces $10 Million Bought Deal Offering of American Depositary Shares

Following the FDA review of data from the U.S. Phase 2 study of opaganib and receipt of its recommendations, RedHill Biopharma Ltd (NASDAQ: RDHL) plans to expand its global Phase 2/3 study of opaganib in patients with severe COVID-19 to the U.S. The study's expansion to the U.S. will help further speed-up enrollment, expand the study to eight countries and approximately 40 recruiting sites. The 464-patient study is over 50% enrolled, and topline data expected in the second quarter of 2021.

RedHill Biopharma Expands Opaganib Global COVID-19 Study To US

TEL AVIV, Israel and RALEIGH, NC, Feb. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced its plans to expand the Company's global Phase 2/3 study of opaganib[1] in patients with severe...

RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.

RedHill (RDHL) doses first patient in phase II/III study of orally-administered RHB-107 (upamostat), an investigational new drug for patients with symptomatic COVID-19 who do not require hospital care.

RedHill (RDHL) Doses First Patient in Phase II/III COVID-19 Study

RedHill Biopharma Ltd (NASDAQ: RDHL) has announced agreements with Cosmo Pharmaceuticals NV to manufacture RedHill's largest selling product in the U.S., Movantik, and RHB-204, currently in a Phase 3 U.S. study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease. Movantik is a prescribed oral peripherally acting mu-opioid receptor antagonist in the U.S. specifically to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.

RedHill Biopharma, Cosmo Pharma In Manufacturing Pact for Movantik, RHB-204

TEL AVIV, Israel and RALEIGH, N.C., Feb. 18, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced agreements with Cosmo Pharmaceuticals NV (SIX: COPN) ("Cosmo") to manufacture two key products;...

RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204

RedHill Biopharma Ltd (NASDAQ:RDHL) announced Wednesday that the first patient was dosed in its US Phase 2/3 study of orally-administered RHB-107 (upamostat), an investigational new drug for patients with symptomatic coronavirus (COVID-19) who do not require hospital care. In a statement, RedHill's CEO Dror Ben-Asher told investors that the company is “positioned at the very forefront of COVID-19 therapeutic research, aiming to address both existing and emerging mutations.

RedHill Biopharma says first patient dosed in ground-breaking RHB-107 Phase 2/3 study of coronavirus outpatients

Abbott Labs

Gritstone Oncology Inc

Moderna

Are you a high-risk stock picker or cautious investor? No matter your answer, there's a stock for you on this list.

News for RedHill Biopharma Stock (RDHL)